Skip to main content

Cystic Fibrosis clinical trials at UCSF

5 in progress, 1 open to eligible people

Cystic fibrosis is a disease that affects the lungs and digestive system. At UCSF, we are doing a clinical trial to test a drug for treatment. We need healthy volunteers and people with cystic fibrosis to give sputum samples. There are three more trials going on, but they are not open for new participants.

Showing trials for
  • CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment

    open to eligible people ages 18-65

    The investigators will collect samples of sputum from healthy volunteers and patients with cystic fibrosis for the purpose of: a) purifying airway mucins for plate-based binding studies and; b) assessment of the effects of carbohydrates on the rheologic properties of the sputum. This study has two hypotheses: 1. Lectins from Pseudomonas aeruginosa and Aspergillus fumigatus bind to airway mucins in a fucose-dependent manner, and this binding can be inhibited by fucosyl glycomimetic compounds. 2. Fucosyl glycomimetics will compete with Pseudomonas aeruginosa lectin (PA-IIL) and Aspergillus fumigatus lectin (AFL) and disrupt lectin-driven mucin cross-linking in CF sputum.

    San Francisco, California

  • A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are heterozygous for F508del and a minimal function mutation (F/MF participants).

    San Francisco, California and other locations

  • A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

    Sorry, accepting new patients by invitation only

    The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.

    San Francisco, California and other locations

  • Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

    Sorry, not accepting new patients

    The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.

    San Francisco, California and other locations

  • Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

    Sorry, accepting new patients by invitation only

    The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as retrospective standard of care patients

    San Francisco, California and other locations

Our lead scientists for Cystic Fibrosis research studies include .

Last updated: